MorphoSys AG

    MorphoSys AG

    NNASDAQ:MOR
    - -
    USD
    - -
    - -
    15.08P/E
    MorphoSys AG
    NASDAQ:MOR
    (Nasdaq Stock Market)

    Recent

    price

    - -

    P/E

    ratio

    15.08

    div

    yld

    - -

    ROIC.AI

    2008
    2009
    2010
    2011
    2012
    2013
    2014
    2015
    2016
    2017
    2018
    2019
    2020
    2021
    2022
    2023
    TTM
    EUR
    0.81
    0.9
    0.96
    0.9
    0.56
    0.8
    0.62
    1.02
    0.47
    0.58
    0.61
    0.57
    2.47
    1.34
    2.04
    1.74
    1.74
    Revenue per Share
    0.15
    0.1
    0.1
    0.09
    0.02
    0.14
    -0.03
    0.14
    -0.57
    -0.6
    -0.45
    -0.81
    0.74
    -3.85
    -1.11
    -1.38
    -1.39
    Basic EPS, GAAP
    0.28
    -0.05
    -0.13
    0.26
    -0.01
    0.85
    -0.33
    -0.31
    -0.47
    -0.45
    -0.28
    -0.67
    -0.11
    -3.8
    -2.8
    -2.18
    -1.45
    Free Cash Flow per Basic Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Dividend per Share
    1.55
    0.12
    0.22
    0.31
    0.34
    0.48
    0.43
    0.57
    0.02
    -0.59
    -0.96
    -1.77
    -0.94
    -4.78
    -5.78
    -7.11
    -7.14
    Book Value per Share
    1.3
    1.44
    1.29
    1.43
    1.81
    3.23
    2.92
    2.72
    3.29
    2.51
    3.52
    2.77
    4.15
    -6.95
    -7.94
    -8.29
    -8.32
    Tangible Book Value per Share
    89
    90
    91
    92
    92
    98
    104
    104
    106
    116
    125
    126
    133
    134
    137
    137
    137
    Basic Weighted Avg Shares
    72
    81
    87
    82
    52
    78
    64
    106
    50
    67
    76
    72
    328
    180
    278
    238
    238
    Sales/Revenue/Turnover
    22.92
    14.08
    11.32
    14.3
    4.7
    13.01
    -9.07
    12.1
    -120.12
    -100.4
    -78.57
    -150.51
    6.12
    -154.57
    -79.32
    -105.28
    -105.22
    Operating Margin (%)
    5
    5
    6
    7
    6
    5
    4
    3
    4
    4
    4
    6
    8
    10
    11
    11
    6
    Depreciation Expense
    13
    9
    9
    8
    2
    13
    -3
    15
    -60
    -70
    -56
    -103
    98
    -514
    -151
    -190
    -190
    Net Income, GAAP
    26.87
    31.22
    30.18
    26.72
    22.47
    30.99
    - -
    27.76
    - -
    - -
    - -
    - -
    - -
    - -
    962.15
    - -
    - -
    Effective Tax Rate (%)
    18.36
    11.07
    10.57
    10.01
    3.74
    17.09
    -4.71
    14.03
    -121.39
    -104.54
    -73.48
    -143.56
    29.87
    -286.43
    -54.29
    -79.63
    -79.6
    Profit Margin (%)
    123
    131
    111
    131
    168
    371
    290
    273
    270
    293
    343
    242
    1,006
    848
    811
    550
    550
    Working Capital
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    40
    315
    322
    688
    622
    622
    LT Debt
    162
    174
    186
    197
    202
    352
    349
    363
    415
    359
    488
    395
    621
    245
    157
    49
    49
    Total Equity
    7.81
    4.65
    3.78
    4.39
    0.93
    2.5
    - -
    2.6
    - -
    - -
    - -
    - -
    - -
    - -
    266.76
    - -
    - -
    Return on Invested Capital (%)
    20.84
    12.05
    58.66
    33.38
    6.5
    33.97
    - -
    28.62
    - -
    - -
    - -
    - -
    - -
    - -
    572.88
    - -
    - -
    Return on Capital (%)
    - -
    12.05
    58.81
    33.43
    6.5
    34.09
    -6.58
    28.72
    -198.03
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)

    Capital Structure

    EUR

    •

    in mil. unless spec.
    Jun'23
    Sep'23
    Dec'23
    ST Debt
    5
    - -
    14
    LT Borrowings
    240
    - -
    613
    LT Finance Leases
    36
    - -
    9
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    34
    - -
    38
    Market Capitalization
    936
    869
    1,226

    Working Capital

    EUR

    •

    in mil. unless spec.
    Jun'23
    Sep'23
    Dec'23
    Total Current Assets
    863
    - -
    814
    Cash, Cash Equivalents & STI
    672
    - -
    683
    Accounts Receivable, Net
    71
    - -
    32
    Inventories
    72
    - -
    62
    Total Current Liabilities
    242
    - -
    264
    Payables & Accruals
    121
    - -
    110
    ST Debt
    5
    - -
    14
    Deferred Revenue
    - -
    - -
    19

    Growth Rates

    EUR

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    -8.68%
    -25.38%
    -68.84%
    Free Cash Flow
    339.64%
    703.79%
    -21.79%
    Net Income, GAAP
    -200.86%
    -156.45%
    25.6%
    Sales/Revenue/Turnover
    38.96%
    69.19%
    -14.37%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    EUR

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2021
    47
    38
    41
    53
    180
    2022
    41
    59
    96
    82
    278
    2023
    62
    53
    64
    59
    238

    Quarterly Earnings Per Share

    EUR

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2021
    -0.32
    0.16
    -0.82
    -2.79
    -3.85
    2022
    -0.9
    -1.72
    -0.9
    - -
    -1.11
    2023
    -0.33
    -0.54
    -0.88
    - -
    -1.38

    Quarterly Dividends Per Share

    EUR

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2021
    - -
    - -
    - -
    - -
    - -
    2022
    - -
    - -
    - -
    - -
    - -
    2023
    - -
    - -
    - -
    - -
    - -
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • gurufocus.com

      Paysafe Launches Video Gaming Arena to Connect Publishers with Millions of Gamers

    • defenseworld.net

      Contrasting Scopus BioPharma (NASDAQ:SCPS) & MorphoSys (NASDAQ:MOR)

    • globenewswire.com

      Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds

    • reuters.com

      Some 330 jobs hit as Novartis closes Morphosys, WiWo reports

    • reuters.com

      Novartis: launch of Morphosys drug by could be 2027 or later

    • accesswire.com

      Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting

    • globenewswire.com

      SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of MorphoSys AG – MOR

    • prnewswire.com

      SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of MorphoSys AG - MOR

    • businesswire.com

      MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market

    • businesswire.com

      MOR STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of MorphoSys AG Is Fair to Shareholders

    • businesswire.com

      MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys' Minority Shareholders

    • accesswire.com

      Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG's Minority Shareholders

    • globenewswire.com

      The State of Massachusetts Issues MOR-EV Approval, Granting Mullen's Class 3 EV Truck a $15,000 Cash Voucher per Vehicle Sold

    • https://www.defenseworld.net

      MorphoSys AG Forecasted to Post Q2 2024 Earnings of ($0.54) Per Share (NASDAQ:MOR)

    • https://www.defenseworld.net

      Trevena, Inc. to Post Q2 2024 Earnings of ($0.37) Per Share, HC Wainwright Forecasts (NASDAQ:TRVN)

    • seekingalpha.com

      MorphoSys: Hold Rating Until The Novartis Deal Closes

    • businesswire.com

      MorphoSys AG Reports First Quarter 2024 Financial Results

    • reuters.com

      Morphosys says Novartis takeover progressing as planned for H1 2024

    • accesswire.com

      MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting

    • accesswire.com

      MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis